Document is current
Any future updates will be listed below
-
Authors
Ravandi, Farhad https://orcid.org/0000-0002-7621-377X
Senapati, Jayastu https://orcid.org/0000-0002-6831-2567
Jain, Nitin
Short, Nicholas J. https://orcid.org/0000-0002-2983-2738
Kadia, Tapan https://orcid.org/0000-0002-9892-9832
Borthakur, Gautam https://orcid.org/0000-0001-7679-6453
Konopleva, Marina https://orcid.org/0000-0002-9347-2212
Wierda, William https://orcid.org/0000-0002-7357-270X
Huang, Xuelin https://orcid.org/0000-0003-1192-9336
Maiti, Abhishek
Issa, Ghayas
Balkin, Hayley
Garris, Rebecca
Ferrajoli, Alessandra
Garcia-Manero, Guillermo https://orcid.org/0000-0002-3631-2482
Alvarado, Yesid https://orcid.org/0000-0002-1652-7937
Kebriaei, Partow
Jabbour, Elias https://orcid.org/0000-0003-4465-6119
Kantarjian, Hagop M. https://orcid.org/0000-0002-1908-3307
- License Information
-
More Information
Article History
Received: 26 July 2024
Revised: 11 September 2024
Accepted: 13 September 2024
First Online: 25 September 2024
Competing interests
: FR has received research funding from Amgen, Astex Pharmaceuticals/Taiho Oncology, Bristol Myers Squibb/Celgene, Syos, AbbVie, Prelude, Xencor, Astellas Pharma, and Biomea Fusion; honoraria from Amgen, Bristol Myers Squibb/Celgene, Syos, AbbVie, and Astellas Pharma; has been a board of directors or advisory committee member for Astex Pharmaceuticals/Taiho Oncology; and has been a consultant for Bristol Myers Squibb/Celgene, Syos, Novartis, AbbVie, AstraZeneca, and Astellas Pharma. NJS has been a consultant for Takeda Oncology, AstraZeneca, Amgen, Novartis, and Pfizer; received research funding from Takeda Oncology, Astellas, and Stemline Therapeutics; and received honoraria from Amgen. TMK has been a consultant for AbbVie, Agios, Bristol Myers Squibb, Genentech, Jazz Pharmaceuticals, Novartis, Servier, and PinotBio; has received research funding from AbbVie, Bristol Myers Squibb, Genentech, Jazz Pharmaceuticals, Pfizer, Cellenkos, Ascentage Pharma, Galectin Therapeutics, Astellas Pharma, AstraZeneca, Amgen, Cyclacel Pharmaceuticals, Delta-Fly Pharma, Iterion Therapeutics, GlycoMimetics, and Regeneron Pharmaceuticals; and has received honoraria from Astex Pharmaceuticals. The remaining authors declare no competing financial interests. EJ has received research grants and consultancy from Amgen, Adaptive Biotechnologies, Ascentage, Autolus, Bristol-Myers Squibb, Pfizer, Takeda, Novartis, Abbvie, Genentech, ASTX, TGRX, TERN, and Johnson and Johnson. HMK has received research funding from AbbVie, Amgen, Ascentage Pharma, Bristol Myers Squibb, Daiichi Sankyo, ImmunoGen, Jazz Pharmaceuticals, and Novartis as well as honoraria from AbbVie, Amgen, Amphista Therapeutics, Ascentage Pharma, Astellas Pharma, Biologix, Curis, Ipsen, KAHR, Novartis, Pfizer, Precision BioSciences, Shenzhen TargetRx, and Takeda Oncology. All the other authors declare no relevant conflict of interest.
